Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Amortizatization of Intangibles (2018 - 2025)

10x Genomics' Amortizatization of Intangibles history spans 8 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles rose 12.18% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $7.6 million, down 2.71%, while the annual FY2025 figure was $7.6 million, 2.71% down from the prior year.
  • Amortizatization of Intangibles for Q4 2025 was $2.0 million at 10x Genomics, up from $2.0 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $7.1 million in Q4 2021 and bottomed at -$4.0 million in Q3 2021.
  • The 5-year median for Amortizatization of Intangibles is $2.0 million (2022), against an average of $2.0 million.
  • The largest YoY upside for Amortizatization of Intangibles was 376.37% in 2021 against a maximum downside of 214.88% in 2021.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $7.1 million in 2021, then tumbled by 72.66% to $2.0 million in 2022, then grew by 1.95% to $2.0 million in 2023, then decreased by 8.8% to $1.8 million in 2024, then rose by 12.18% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Amortizatization of Intangibles are $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $1.8 million (Q2 2025).